LinaclotideLocally acting intestinal peptide
Linaclotide activates guanylate cyclase-C receptors at the intestinal surface. It is used in particular constipation-related conditions, where bowel frequency and abdominal symptoms need to be assessed separately.
What is Linaclotide?
Linaclotide is a locally acting intestinal peptide medicine used for particular constipation conditions, including irritable bowel syndrome with constipation (IBS-C). The diagnosis and product’s age restrictions matter. 1 2
How it works
It activates guanylate cyclase-C receptors in the intestine, increasing fluid secretion into the bowel and helping stool pass. Systemic absorption is limited. 2
Effects studied
What does the evidence show?
The archive includes a controlled IBS-with-constipation trial and product information. Indications and age restrictions require checking against the current local product.
What happens in the intestine
Activating guanylate cyclase-C increases signalling that promotes fluid secretion into the bowel. Linaclotide acts mainly within the gastrointestinal tract, with very limited systemic exposure. This local action helps explain its use, but significant adverse effects can still occur.
Two outcomes that should not be collapsed
A person may have more frequent bowel movements without the same degree of improvement in abdominal pain. Trials therefore need to define both the constipation and symptom outcomes they measure. The retained clinical paper concerns irritable bowel syndrome with constipation, not every cause of infrequent stools. 1
Why the diagnosis matters
Constipation can have different causes, including medicines or a mechanical obstruction. Increasing intestinal secretion does not resolve all of them. Clinical assessment and the relevant product information determine whether this treatment fits the cause of the symptoms.
Diarrhoea is a meaningful trade-off
The same fluid-secretion effect that can help constipation can produce diarrhoea and dehydration. Special restrictions concerning children and suspected obstruction are important, but exact eligibility should come from the current product label. Limited absorption should never be translated into an assurance that any person can safely try the medicine. 2
Safety & status
Diarrhoea can be severe and lead to dehydration. The product has specific restrictions for children and for suspected or known mechanical bowel obstruction. 2
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Does it work mainly in the gut?
Yes. Its action is primarily local in the intestine, with limited systemic absorption. 2
Is it a treatment for every type of constipation?
No. The cause of constipation and the approved product indication need to be distinguished, especially when obstruction is possible. 2
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Linaclotide: paper 10.1038/ajg.2012.254 Research reference · Retained archive reference; not independently checked for this draft.
- Linaclotide: www.rxabbvie.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.